Simrat Randhawa, M.D., serves as the Chief Medical Officer at Dianthus Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies for patients with severe autoimmune and inflammatory diseases. Dr. Randhawa brings a wealth of experience and expertise to her role, having spent over two decades in the biopharmaceutical industry. She has a strong track record of leading successful clinical development programs and bringing new therapies to market. Prior to joining Dianthus Therapeutics, Dr. Randhawa held several key leadership positions at prominent biopharmaceutical companies. She served as the Chief Medical Officer at Tiziana Life Sciences, where she oversaw the clinical development of novel immunomodulatory therapies for autoimmune diseases and cancer. Before that, she was the Senior Vice President of Clinical Development at Alexion Pharmaceuticals, where she played a pivotal role in the development and approval of several groundbreaking treatments for rare diseases. Dr. Randhawa's expertise in clinical development, regulatory affairs, and medical affairs has been instrumental in advancing innovative therapies and improving patient outcomes. As Chief Medical Officer at Dianthus Therapeutics, Dr. Randhawa is responsible for overseeing the company's clinical development strategy and execution. She leads a team of dedicated professionals in designing and implementing clinical trials to evaluate the safety and efficacy of Dianthus' pipeline of novel therapeutics. Dr. Randhawa's strategic vision and leadership are crucial in guiding the company's mission to develop transformative treatments for patients with severe autoimmune and inflammatory diseases. Her commitment to advancing medical science and improving patient care is evident in her contributions to the field and her role at Dianthus Therapeutics.